Deep Track Capital, LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Deep Track Capital, LP disclosed 65 US equity positions worth $3.1bn in its Q2 2025 13F filing. The largest position was GH at 7.1% of the reported book, followed by IONS and PTGX. Against the Q1 2025 filing, it opened 7 new positions, added to 18 and reduced 10 among the top 50 holdings.
What did Deep Track Capital, LP own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | GH GUARDANT HEALTH INC | Healthcare | 7.1% | $221.2m | 4,250,000 | -22% | reduced |
| 2 | IONS IONIS PHARMACEUTICALS INC | Healthcare | 6.2% | $193.3m | 4,891,544 | 7% | added |
| 3 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 5.8% | $179.4m | 3,245,899 | 8% | added |
| 4 | DVAX DYNAVAX TECHNOLOGIES CORP | 5.7% | $176.5m | 17,791,486 | 0% | held | |
| 5 | INSM INSMED INC | Healthcare | 5.7% | $176.1m | 1,750,000 | 587% | added |
| 6 | AKERO THERAPEUTICS INC | 5.2% | $162.4m | 3,042,598 | -5% | reduced | |
| 7 | IMVT IMMUNOVANT INC | Healthcare | 4.9% | $152.0m | 9,500,000 | 0% | held |
| 8 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 4.3% | $132.7m | 14,294,420 | 0% | held |
| 9 | APLSUSD APELLIS PHARMACEUTICALS INC | 3.9% | $121.2m | 7,000,000 | 40% | added | |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 3.9% | $120.6m | 3,650,000 | 19% | added |
| 11 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 3.4% | $106.5m | 5,133,917 | 25% | added |
| 12 | ETNBGBP 89BIO INC | 3.0% | $93.3m | 9,500,000 | 2% | added | |
| 13 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 2.7% | $83.7m | 801,371 | – | new |
| 14 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 2.4% | $75.2m | 5,380,449 | 0% | held |
| 15 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 2.3% | $70.9m | 1,750,000 | 18% | added |
| 16 | PCVX VAXCYTE INC | Healthcare | 2.2% | $69.9m | 2,150,000 | 187% | added |
| 17 | NRIX NURIX THERAPEUTICS INC | Healthcare | 2.2% | $69.1m | 6,064,910 | 10% | added |
| 18 | GERN GERON CORP | Healthcare | 1.9% | $60.6m | 43,000,000 | 13% | added |
| 19 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 1.8% | $56.5m | 1,800,000 | 28% | added |
| 20 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.6% | $49.1m | 1,350,000 | 0% | held |
| 21 | MAZE MAZE THERAPEUTICS INC | 1.6% | $48.5m | 3,948,910 | 21% | added | |
| 22 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 1.5% | $45.7m | 700,000 | 0% | held |
| 23 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.4% | $42.3m | 1,350,000 | 35% | added |
| 24 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.3% | $41.6m | 2,233,148 | -5% | reduced |
| 25 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 1.3% | $40.7m | 2,000,000 | 0% | held |
| 26 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.2% | $38.9m | 900,000 | -68% | reduced |
| 27 | AUTL AUTOLUS THERAPEUTICS PLC | Healthcare | 1.2% | $38.4m | 16,852,147 | -6% | reduced |
| 28 | METSERA INC | 1.0% | $31.1m | 1,094,408 | 0% | held | |
| 29 | 430 TERNS PHARMACEUTICALS INC | 0.9% | $28.0m | 7,495,000 | 34% | added | |
| 30 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 0.9% | $27.9m | 1,401,938 | 0% | held |
| 31 | ABVX ABIVAX SA | 0.9% | $26.6m | 3,480,144 | -3% | reduced | |
| 32 | JBIO JADE BIOSCIENCES INC | 0.8% | $25.1m | 2,509,301 | – | new | |
| 33 | MBX MBX BIOSCIENCES INC | Healthcare | 0.8% | $25.0m | 2,188,592 | -28% | reduced |
| 34 | CMPS COMPASS PATHWAYS PLC | Healthcare | 0.8% | $24.7m | 8,831,007 | -0% | held |
| 35 | GHRS GH RESEARCH PLC | 0.8% | $24.4m | 2,000,000 | 0% | held | |
| 36 | BCAX BICARA THERAPEUTICS INC | 0.7% | $22.5m | 2,426,657 | 21% | added | |
| 37 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 0.7% | $21.5m | 1,918,798 | 33% | added |
| 38 | ENGENE HOLDINGS INC | 0.5% | $16.6m | 4,557,575 | 0% | held | |
| 39 | BRD1EUR MIND MEDICINE MINDMED INC | 0.5% | $16.2m | 2,500,000 | 0% | held | |
| 40 | UPB UPSTREAM BIO INC | 0.5% | $15.8m | 1,442,767 | -37% | reduced | |
| 41 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.5% | $14.7m | 3,442,833 | 0% | held |
| 42 | MERUS N V | 0.5% | $14.5m | 275,000 | – | new | |
| 43 | HELP CYBIN INC | 0.4% | $12.8m | 1,529,987 | 0% | held | |
| 44 | CDTX CIDARA THERAPEUTICS INC | 0.4% | $12.2m | 250,000 | – | new | |
| 45 | BCYC BICYCLE THERAPEUTICS PLC | Healthcare | 0.3% | $8.4m | 1,203,244 | 57% | added |
| 46 | CBIO CRESCENT BIOPHARMA INC. | 0.2% | $7.3m | 453,686 | – | new | |
| 47 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.2% | $6.6m | 500,000 | – | new | |
| 48 | NVAX NOVAVAX INC | Healthcare | 0.2% | $6.3m | 998,542 | -34% | reduced |
| 49 | IVVD INVIVYD INC | Healthcare | 0.2% | $6.1m | 8,585,980 | -12% | reduced |
| 50 | RAPT RAPT THERAPEUTICS INC | 0.2% | $6.0m | 751,422 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.